More stem cell progress in stroke as Neuralstem gets Chinese trial go-ahead
This article was originally published in Clinica
Executive Summary
China has strengthened its reputation as a location conducive to stem cell research by granting regulatory approval to a clinical trial for a regenerative therapy developed by the US firm Neuralstem, for motor deficits due to ischaemic stroke.